Clinical Trial Update: Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pembrolizumab monotherapy and combination therapy in advanced solid tumors and lung cancer; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Small Cell Lung Cancer
• Solid Tumor

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Solid Tumor, Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2021-03-22